Skip to main content
DongKookPharmaceuticalCo.,Ltd. logo

DongKookPharmaceuticalCo.,Ltd. — Investor Relations & Filings

Ticker · 086450 ISIN · KR7086450004 KO Manufacturing
Open in API
Filings indexed 159 across all filing types
Latest filing 2025-03-13 Audit Report / Informat…
Country KR South Korea
Listing KO 086450

About DongKookPharmaceuticalCo.,Ltd.

https://www.dkpharm.co.kr/en/

DongKook Pharmaceutical Co., Ltd. is a pharmaceutical company engaged in the research, development, manufacturing, and distribution of medical products. Established in 1968, the company focuses on improving human health and quality of life. Its product portfolio includes prescription and non-prescription drugs, with key therapeutic areas in anesthetics, contrast media, anti-cancer agents, antibiotics, and oral healthcare treatments. The company operates its own Active Pharmaceutical Ingredient (API) synthesis facilities and invests in research and development to create innovative therapeutic solutions. It provides both finished products and raw materials to domestic and international markets.

Recent filings

Filing Released Lang Actions
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from Dongkook Pharmaceutical titled 'Audit Report Submission' (감사보고서 제출). It provides the auditor's opinion (unqualified/appropriate), key financial data (assets, liabilities, revenue, profit), and confirms the receipt of the audit report. While it contains financial data, it is a formal notification of the audit report's submission to the regulatory body (DART), which fits the definition of an Audit Report/Information (AR) filing. FY 2024
2025-03-13 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 100% confidence The document is a comprehensive 'Audit Report' (감사보고서) for Dongkook Pharmaceutical Co., Ltd. for the fiscal year ending December 31, 2024. It includes the independent auditor's report, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a formal, full-year financial disclosure document, not an announcement or a summary, and therefore fits the 'Audit Report' (AR) category. FY 2024
2025-03-13 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted by Dongkook Pharmaceutical regarding the scheduling of their Annual General Meeting (AGM) on a 'concentrated date' (a common regulatory requirement in South Korea). It explains the reasons for choosing this date and provides the meeting details. Since it is a regulatory notification regarding meeting logistics rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2025-03-06 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a formal 'Notice of General Meeting of Shareholders' (주주총회소집공고) for Dongkook Pharmaceutical's 57th Annual General Meeting. It includes the meeting agenda, voting procedures (including electronic voting), and detailed management information such as director activity reports, remuneration, and business overviews. While it contains management information, the primary purpose of this specific document is to formally notify shareholders of the upcoming meeting and provide the necessary materials for their participation, which is the standard function of a Proxy Solicitation & Information Statement (PSI) in the Korean regulatory context.
2025-03-06 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) issued by Dongkook Pharmaceutical. It outlines the date, location, agenda items (such as approval of financial statements, election of directors, and remuneration limits), and information regarding electronic voting. This document is a standard proxy solicitation material sent to shareholders to inform them of the upcoming meeting and the matters to be voted upon, which fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-02-13 Korean
현금ㆍ현물배당결정
Notice of Dividend Amount Classification · 100% confidence The document is a formal announcement from Dongkook Pharmaceutical regarding the decision to pay cash dividends. It specifies the dividend amount per share, the total dividend amount, the record date, and the expected payment date. This fits the definition of a 'Notice of Dividend Amount' (DIV).
2025-02-06 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.